Prasol Chemicals Q1 FY27 earnings call

What moved the numbers, as management explained it

• Inventory procured at lower prices and held into a rising price environment added ~₹25 cr to Q1 gross profit, flagged as non-structural. (one-off)
• Sharp rise in acetone/petrochemical prices on West Asia conflict and Strait of Hormuz disruption lifted average selling price.
• Volume growth was in the mid-single digit range with demand strong across all sectors, supported by 1,600+ diversified customers.
• Foreign exchange gains contributed an additional ₹0.92 cr to Q1 EBITDA. (one-off)
• Revenue mix held at 40% acetone / 40% phosphorus / 20% other, with a structural shift toward higher derivatives supporting margin profile.

The numbers management led with

• Phase 1 capex: ₹250-300 cr over next 2 years; ₹50-60 cr on land/infrastructure, balance across 10-14 products
• Phase 1 capacity addition: 60,000 tons addition to combined 98,000 TPA; new total ~150,000-160,000 tons
• Mahad utilization trajectory: 13% in FY24 → 44% in FY26 → 60%+ in Q1 FY27 → 70%+ by FY27 year-end
• Antibacterial drug capacity plan: Target 100+ tons/month after mechanical completion in Jan and 60-90 day trial runs

The company's filed results for this quarter are not on file with us yet; these are management's own figures from the call.

Guidance on this call

By business

Balance sheet, capex and funding

• Net worth ₹448.5 cr as of 31-Mar-2026; gross debt ₹110.1 cr; net debt-to-equity 0.19x
• IPO net proceeds of ₹76.4 cr fully utilized - ₹60 cr for debt repayment and ₹16.4 cr for general corporate purposes
• Net working capital cycle 50 days at end FY26; normalized range 60-70 days
• Phase 1 capex of ₹250-300 cr over next 2 years, to be funded through internal accruals and potentially some additional debt
• Phase 2 capex of ~₹250-300 cr planned for new R&D products; product identification, site preparation and regulatory approvals in progress

The industry, as management sees it

Management sees India as the global chemical manufacturing hub for the next 10-15 years, with multiple multinationals actively diversifying their supply chains to India. European chemical industry described as 'in turmoil' with utility costs having 'gone haywire', forcing closures and M&A. China+1 theme explicitly cited as a structural tailwind.

Risks management named

• Geopolitical environment (West Asia conflict, Strait of Hormuz) and crude/petrochemical price volatility
• Freight cost increases and trade policy uncertainty impacting exports
• Currency fluctuations affecting forex gain/loss
• Loss of some Middle East/African shipments due to West Asia war
• Heavy dependence on imported acetone raw material pending new domestic sources

Not answered directly

• Mahad plant Q1 EBITDA contribution (deferred — CFO to revert)
• Khopoli vs Mahad breakup of 60,000-ton Phase 1 capacity addition (to be shared in H2)

Asked for a number, answered without one

• Mahad plant Q1 FY27 EBITDA contribution: Said Mahad is both PBT and EBITDA positive but did not give a number, stating 'The exact number I will work out and revert back.'

Every question, with its answer

1. 1. Phase 1 capex and new product pipeline

   Nirav Jimudia, Anvil Wealth39:47

   Question. On the Phase 1 capex of 60,000 tons, how much of this would be for the newer products — mining, antibacterial drug, lubricant additives with impurity focus? What is the product lifecycle and recurring revenue potential, and any market size / revenue potential for each?

   Answer, Nishith Shah, Chairman and Whole-Time Director. Lubricant front: bringing up existing capacity by 50-70% via debottlenecking (re-engineered agitator designs cut reaction time, e.g., 10 hours to 6 hours) with minor expense; results in 2-3 months. Antibacterial drug: R&D done, samples approved by MNC, mechanical completion by January, trial runs 60-90 days, expecting volumes in coming year — this is a long-life product. Mining chemical: in pipeline, 3-4 years of work, results over next 2-3 years. All three driven by specific MNC demand.

   Follow-up. So the 60,000 tons expansion is more of an extension of existing products where we reach peak utilization at Khopoli?

   Answer. Correct. Philosophy: once we reach 75-85% of installed capacity and have 3-4 year visibility from end users, we build the next stream. We have 10 streams for one lubricant product, 3-4 for others, 5 hydrogenation reactors — each stream meeting a specific customer's quality requirement (impurity profile to 0.05 vs 0.2% standard).

2. 2. Growth strategy philosophy

   Nirav Jimudia, Anvil Wealth42:42

   Question. So to be clear, we are targeting application-based growth rather than customer-based growth?

   Answer, Nishith Shah, Chairman and Whole-Time Director. Correct assumption.

3. 3. Raw material sourcing and storage

   Nirav Jimudia, Anvil Wealth42:49

   Question. On acetone raw material — a new source is coming up on the east coast but with higher freight. Are we building additional storage tanks / infrastructure to enable bulk buying and diversify sourcing?

   Answer, Nishith Shah, Chairman and Whole-Time Director. Perfect analysis. Have set aside ₹25 cr towards storage tank with floating roof (to avoid acetone vaporization) at adjoining Khopoli land, to be invested in next one year. Indian shipping will increase exponentially; manufacturers working on special barge system to make transport cheaper than Gujarat-to-Bombay. Soon will have multiple purchase and import choices — we are in a sweet spot.

4. 4. Volume vs value growth in FY27

   Nirav Jimudia, Anvil Wealth43:47

   Question. You mentioned ~30-35% topline growth this year. Given last year was at 70-72% utilization on 99,000 tons, how much of this 35% could be volume growth?

   Answer, Nishith Shah, Chairman and Whole-Time Director. Volume alone may not be the right guidance. As you move up to second/third derivatives, a ₹10 item becomes ₹13-15-17. So you may have single-digit volume growth but 40% revenue growth. Volume depends on which stage of chemistry you are selling — higher cost, lower volume. Hard to give volume guidance.

   Partly answered.

5. 5. Geopolitical impact on exports

   Arjun Khanna, Kotak Mahindra Asset Management44:33

   Question. On the supply chain issues and West Asia conflict — exports to 65+ countries, 1,600 customers. Any business impact? Freight and energy costs moving up, European clients impacted. How is the strong outlook for the year realistic?

   Answer, Nishith Shah, Chairman and Whole-Time Director. Highly diversified. Some shipments to Africa/Middle East affected, substituted by Europe. Exports 27% in Q1 and growing. Largest customer is only ₹55-60 cr of our turnover, present in multiple geographies, so they absorb the local adjustments. We continue to export to US despite extra freight/duties and to China as well. Without the war, exports would have been 10% higher, but diversification has kept growth on track.

6. 6. Phase 1 capex execution and phasing

   Arjun Khanna, Kotak Mahindra Asset Management45:23

   Question. On Phase 1 capex of ₹250-300 cr — how much already done and what is the phasing of output across products over the next 2 years?

   Answer, Nishith Shah, Chairman and Whole-Time Director. Land already bought, detailed engineering complete. Roughly 10-14 products, including ₹25 cr storage facility at Khopoli, plus infrastructure (roads, firefighting). Projects come every 3-6 months: antibacterial in 6 months, lubricant volume increase before March, two more by March (may slip 30 days into next year). Always 2-3 projects at 80-90%, some at 50%, some on drawing board. All 10-12 projects to be spent and installed in 12-18 months from today.

7. 7. Mahad plant trajectory

   Arjun Khanna, Kotak Mahindra Asset Management46:26

   Question. Mahad was EBITDA positive in Q1. As the year progresses, how do you see utilization and new projects pan out at Mahad?

   Answer, Nishith Shah, Chairman and Whole-Time Director. Working beautifully. Utilization moved from 12% to 60%-plus; year-end to 70%+. The new 20-acre adjoining land helps share basic costs (same engineering team, works manager, admin, safety, utility, ETP) and adds to ROCE in 3-4 years. You never jump from investment to 100% utilization; you go 40%→50%→60%→70%→80%→90%. Mahad is the 'New Bombay' vs Khopoli as 'Old Bombay' — 10-acre slabs in a perfect rectangular layout, on a hilltop in a good industrial estate. Very optimistic on Mahad.

8. 8. Antibacterial drug commercialization

   Aksh Vashishth, Edelweiss47:37

   Question. On the antibacterial product — it's already in the portfolio and we already supply. With this new technology advancement, how do you see the volume scale up in the next few months after sample approval from the global player?

   Answer, Nishith Shah, Chairman and Whole-Time Director. Old technology was a 10-step process; new proprietary process is 3-3.5 steps. Have contract understanding with the end user. Once samples get approved, looking at 100+ tons/month to start, then growing as other MNCs use this antibacterial application. We expect cost-competitive edge because, to our knowledge, we will be the only one doing it through this process. NDA with MNC prevents more detail at this stage.

   Partly answered.

9. 9. Mahad plant EBITDA contribution

   Aksh Vashishth, Edelweiss1:04:32

   Question. Mahad plant touched close to 60% utilization in Q1. What was the EBITDA contribution from Mahad in Q1?

   Answer, Nishith Shah, Chairman and Whole-Time Director. It is both PBT positive and EBITDA positive. Exact number will be worked out and shared separately.

   Not answered directly.

10. 10. FY27 EBITDA guidance scope

    Aksh Vashishth, Edelweiss1:04:51

    Question. FY27 EBITDA guidance of ₹240-250 cr — is the ₹25 cr inventory gain in Q1 included or excluded from this guidance?

    Answer, Nishith Shah, Chairman and Whole-Time Director. Excluding that. We want to give very clear guidance — the ₹25 cr and forex gain are not from our operations but from circumstances. Adjusted EBITDA guidance of ₹240-250 cr is the right way to guide investors.

11. 11. Capacity, working capital and R&D pipeline

    Dhimant, ITI Mutual Fund1:05:26

    Question. We are expanding from 98,000 tons by 60,000 in the expansion plan — total capacity ~160,000 tons. Can you walk through the working capital cycle and how you identify areas to concentrate? Of the 13 new R&D products, what trajectory will they undergo?

    Answer, Nishith Shah, Chairman and Whole-Time Director. Total capacity 150,000-160,000 tons. Working capital generally 60-70 days, slightly elevated at March-end due to year-end push. Good credit from Acetone and Phosphorus suppliers, so comfortable on cash flows. On products: we participate in global exhibits; MNC scientists come with application tweaks (e.g., 10 ppm to 0.5 ppm impurity, or 99.75% to 99.9% purity). Tighter purity moved the product from hazardous to non-hazardous cargo, saving 40-50% in supply to Europe. The 13 commercialized products are in lubricants, agro, mining, home & personal care, pharma areas.

12. 12. Revenue mix evolution

    Dhimant, ITI Mutual Fund1:06:59

    Question. The 40-40-20 mix — will it remain sacrosanct or will the specialty (20%) grow faster?

    Answer, Nishith Shah, Chairman and Whole-Time Director. Was 30%-30%-40% 7-8 years back, now 40-40-20, want to bring 20% down to 10% in 5 years. Philosophy: import best product, understand market for 4-5 years, capture >50% of Indian market, then in-house manufacture. Distribution margins 5-6%, manufacturing margins 15%. Take that as policy — every investment gives decent return.

13. 13. Segment-level growth outlook

    Dhimant, ITI Mutual Fund1:07:28

    Question. Out of Acetone, Phosphorus and Specialty, which segment will be more contributory in terms of growth and margins over the medium term?

    Answer, Nishith Shah, Chairman and Whole-Time Director. Both Acetone and Phosphorus are equally on the table. R&D aggressively looking at newer products in all five sectors. Don't see a major needle mover — maybe 0.5% shift between categories.

14. 14. Plant flexibility and R&D capabilities

    Dhimant, ITI Mutual Fund1:07:43

    Question. Are our plants multi-purpose or dedicated? Is there a process know-how we have mastered that allows us to churn so many products? Hydrogenation capability you mentioned?

    Answer, Nishith Shah, Chairman and Whole-Time Director. Till 2020 Prasol was more of a development company; last 5-6 years R&D is internalized. Built a multi-purpose plant to run various experiments based on 30-year experience; built fixed bed reactors, various temperature/pressure reactors. Invested ₹15 cr in two plants for in-house R&D (vs. earlier external job work). Building additional 4,000 sq ft lab in next 5-6 months with ₹15-20 cr investment for a special application lab. Will take the company to the next level.

15. 15. EBITDA guidance conservatism

    Gaurav Shukla, Finvestors1:08:36

    Question. You have given EBITDA guidance of ₹240-250 cr and Q1 already delivered ₹90 cr. Is the guidance too conservative?

    Answer, Nishith Shah, Chairman and Whole-Time Director. We are conservative temperamentally. The ₹25 cr came from inventory gain and forex gains in Q1. With normalization and geopolitical uncertainty (Q2 almost over), no clarity on the situation. Better to be conservative. Still 70% minimum EBITDA growth YoY. Don't want to revise later by blaming war, etc. Numbers given are what we believe we can deliver.

16. 16. FY27 EBITDA margin guidance

    Gaurav Shukla, Finvestors1:08:36

    Question. What will be the blended EBITDA margin for FY27?

    Answer, Nishith Shah, Chairman and Whole-Time Director. End of year EBITDA margin guided at 15-16% in that range.

17. 17. Q1 inventory build explanation

    Gaurav Shukla, Finvestors1:08:36

    Question. Q1 saw a significant inventory build — was this for strategic purpose or some other reason?

    Answer, Nishith Shah, Chairman and Whole-Time Director. For 25 years, year-on-year, we have increased sales in volume and value. Towards end of January, we start stocking up for April to come into force. Started importing in Jan/Feb, little did we know a war would come in late February and cause price escalation. We do not speculate on raw material, period. Buy based on calculation and need. Happened to be at a sweet spot — we got the advantage and disclosed it — but do not speculate as a rule.

18. 18. R&D pipeline composition and conversion rate

    Divesh Chainani, Equentis Wealth Advisory1:10:08

    Question. 40 new products are in the R&D pipeline — are these daily-use products or something different? Will you require additional capex for these 40 products?

    Answer, Nishith Shah, Chairman and Whole-Time Director. Not all 40 get commercialized; rule of thumb is 15-20%. Each goes through costing, equipment review; the route the chemist elects may not be economical. ~25-30 of 40 are forward integration of existing products (easier, MNC knows tweaking). Other ~25 are new chemistry — e.g., converting what was earlier waste (disposed at ₹10) into input for next chemistry sold at ₹80 with conversion cost of ₹15-20. Goal is zero-waste output company — even gases being put to use. These 40 are part of waste-to-product development for future applications.

19. 19. Land bank for new chemistry

    Divesh Chainani, Equentis Wealth Advisory1:10:53

    Question. For the newer chemistry, will the spare land bank at Mahad and Khopoli be used or will you need a separate land bank?

    Answer, Nishith Shah, Chairman and Whole-Time Director. Newer chemistry will use land bank already purchased. One or two products in very advanced stage — applying for environmental clearance now (typically 9-12 months). R&D done, detailed engineering done, costing done, land marked for utilization. Interconnected with old plant facilities.

20. 20. Mahad peak utilization and capacity split

    Divesh Chainani, Equentis Wealth Advisory1:11:22

    Question. Mahad is currently underutilized vs the 75-80% target — by what year can Mahad reach peak utilization? Is the 60,000 tons addition entirely for Khopoli since Mahad is underutilized?

    Answer, Nishith Shah, Chairman and Whole-Time Director. By end of this year, existing products at Mahad will cross 70%+. Coming 1.5-2 years, expanding in every product. We add capacity when customers have a definite growth plan — we are ready when they are ready. The 60,000 tons addition has a breakup between Khopoli and Mahad, but I haven't brought that to the table — will share in the second half.

    Not answered directly.

Topic by topic, in the order it was spoken

In their words